GleamWall
中文EN

LMRI Lumexa Imaging Holdings, Inc.

Services-Medical Laboratories · Nasdaq · SEC CIK 2071288 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets65.4%
Debt / equity1.32x
Current ratio1.52x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$271.97M$264.16M$252.54M$258.94M$251.40M$245.00M
SG&A expense$30.02M$24.40M$20.34M$17.08M$18.69M$17.49M
Operating income$28.11M$23.04M$19.41M$30.34M$27.68M$25.54M
Interest expense$15.67M$16.22M$16.33M$30.58M$30.10M$29.85M
Pretax income$11.79M$5.76M$3.08M-$237,000-$2.42M-$4.31M
Income tax$4.61M$3.02M$1.36M$3.26M$4.81M$3.38M
Net income$7.18M$2.75M$1.72M-$3.50M-$7.23M-$7.69M
EBITDA$38.44M$33.12M$29.33M$39.99M$36.96M$34.59M
EPS (basic)0.070.030.02-0.05-0.10-0.11
EPS (diluted)0.070.030.02-0.05-0.10-0.11
Weighted avg. shares (diluted)96.26M96.04M95.98M69.53M69.53M69.52M
Balance sheet
Cash & equivalents$90.01M$69.70M$51.23M$191,000$4.75M$7.30M
Current assets$278.31M$256.42M$221.89M———
PP&E, net$158.85M$156.06M$150.13M———
Goodwill$807.55M$807.55M$807.55M———
Intangibles$38.58M$39.72M$40.24M———
Total assets$1.83B$1.81B$1.76B———
Current liabilities$183.46M$178.35M$157.93M———
Short-term debt$15.55M$14.33M$13.44M———
Long-term debt$821.52M$819.75M$816.97M———
Total debt$837.07M$834.08M$830.41M———
Total liabilities$1.20B$1.19B$1.16B———
Shareholders' equity$634.08M$615.06M$599.62M$167.11M$162.18M$161.00M
Net debt$747.06M$764.38M$779.18M———
Shares outstanding96.06M96.07M96.08M———
Cash flow statement
Operating cash flow$34.81M$32.80M$2.93M$11.86M$2.07M-$13.96M
Capital expenditure$14.21M$9.67M$5.31M$13.63M$4.60M$1.00M
Free cash flow$20.60M$23.13M-$2.38M-$1.77M-$2.53M-$14.96M
Investing cash flow-$14.05M-$13.64M-$5.27M-$13.67M-$4.17M-$720,000
Financing cash flow-$454,000-$685,000-$5.26M-$2.75M-$462,000-$4.15M
Depreciation & amortization$10.33M$10.08M$9.92M$9.65M$9.28M$9.05M
Stock-based compensation$12.34M$12.74M$12.27M$8.31M$8.35M$6.37M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.